TCR1188-ABC cells

Phase 1

UUniversity of Pennsylvania

TCR1188-ABC cells is one of 39 therapeutic programs targeting Cholangiocarcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

CholangiocarcinomaRecruiting

CholangiocarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

45 competitors in Cholangiocarcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

19 2

Rocaltrol

Camptosar

Colcrys

Zykadia

Ixempra

Wellcovorin

GGlaxo Dba Glaxosmithkline

Approved

—8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

14 9

Tecentriq

Roche

Phase 3

3 10

Cotellic

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2042

Phase 1Recruiting

Cholangiocarcinoma

NCT07594067

Clinical

Trials by Indication[1]

Cholangiocarcinoma1 trial

Phase I, Open-Label Study of Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells (TCR1188-ABC)

Recruiting·UUniversity of Pennsylvania·Phase 1·NCT07594067·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TCR1188-ABC cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for TCR1188-ABC cells. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Pennsylvania company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUniversity of Pennsylvania

TCR1188-ABC cells

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2042

Trials by Indication[1]

Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News